Namenda Sales Data
| Rank 29 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Namenda U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 29 ( 2) |
$434,766 | -6.00% | 1,704 | -9.12% |
| Q3 2013 | 27 (2) |
$462,497 | -1.52% | 1,875 | -4.14% |
| Q2 2013 | 25 | $469,630 | 4.67% | 1,956 | -2.73% |
| Q1 2013 | 25 | $448,659 | -1.32% | 2,011 | -3.55% |
| Q4 2012 | 25 ( 2) |
$454,671 | 5.09% | 2,085 | -0.10% |
| Q3 2012 | 27 (8) |
$432,634 | 6.05% | 2,087 | 4.61% |
| Q2 2012 | 35 (2) |
$407,937 | 4.16% | 1,995 | -2.87% |
| Q1 2012 | 37 | $391,638 | 2.71% | 2,054 | 1.83% |
| Q4 2011 | 37 (1) |
$381,310 | 6.06% | 2,017 | -0.44% |
| Q3 2011 | 36 (2) |
$359,537 | -2.67% | 2,026 | -2.27% |
| Q2 2011 | 34 (5) |
$369,408 | 5.72% | 2,073 | -0.86% |
| Q1 2011 | 39 | $349,433 | n/a | 2,091 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
